Actively Recruiting

Phase 3
Age: 15Years - 24Years
All Genders
NCT07464886

Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth

Led by University of Cincinnati · Updated on 2026-03-11

160

Participants Needed

1

Research Sites

248 weeks

Total Duration

On this page

Sponsors

U

University of Cincinnati

Lead Sponsor

N

National Center for Complementary and Integrative Health (NCCIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The primary goal is to investigate to what extent changes in glutamate and glutathione modulation and functional integration between brain networks associated with emotion and attention regulation are associated with treatment response in mildly depressed youth.

CONDITIONS

Official Title

Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth

Who Can Participate

Age: 15Years - 24Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  1. age between 15 years, 0 months to 24 years, 11 months old;
  2. presenting with mild depression, defined by meeting DSM-5 criteria for a current major depressive episode, mild severity, or persistent depressive disorder, or other specified depressive disorder (depressive episode with insufficient symptoms to meet criteria for a major depressive episode);
  3. medication-naïve or medication free for at least 5 half-lives since the last use of a psychoactive medication, with the exception of stimulants for ADHD;
  4. if on ADHD stimulant medication over 2 months prior to screening, willing to maintain stimulant dose constant during the study participation;
  5. Tanner stage greater than or equal to III;
Not Eligible

You will not qualify if you...

  1. significant suicidal risk, defined by suicidal ideation of type 3, 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months, or any lifetime suicidal attempts;
  2. current major depressive episode, moderate or severe
  3. current or lifetime history of manic or hypomanic episodes, and/or diagnosis of bipolar disorder;
  4. current or lifetime history of psychotic disorders, and/or prior diagnosis of schizophrenia spectrum disorders;
  5. active or current substance use disorders in the last 3 months, except cannabis or alcohol use disorder, mild;
  6. diagnosis of autism spectrum disorder, pervasive developmental disorder, obsessive-compulsive disorder, post-traumatic stress disorders, Tourette's syndrome
  7. any contraindication to MRI scanning;
  8. pregnancy;
  9. history of major neurological disorder (e.g, epilepsy), or head trauma with > 10 minutes loss of consciousness;
  10. intellectual disability (IQ less than or equal to 70), as determined by the Weschler Abbreviated Scale of Intelligence (WASI);
  11. previous participation in any mindfulness-based treatment;
  12. initiating psychotherapy within 2 months prior to screening, or planning to initiate psychotherapy during study participation; if on therapy, frequency and type should remain stable for 2 months prior to enrollment and during study participation;
  13. no current diagnosis of asthma
  14. history of allergic reaction to N-acetylcysteine

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience

Cincinnati, Ohio, United States, 45219

Actively Recruiting

Loading map...

Research Team

F

Fabiano Nery, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here